Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

IMW 2019 | Implications of IMW 2019 on nursing practices

Tanya Burton • 14 Sep 2019
IMW 2019
Amyloidosis Multiple Myeloma Rare Diseases Dexamethasone

Tanya Burton University Hospital of Wales, Cardiff, UK, shares her highlights and reflections from the nursing symposium attached to the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Tanya Burton

Multiple myeloma: what needs to change to improve care? 1:03
Multiple myeloma: what needs to change to improve care?
Tanya Burton • 2 Apr 2019
Self-administration of bortezomib in multiple myeloma: results from Cardiff 2:18
Self-administration of bortezomib in multiple myeloma: results from Cardiff
Tanya Burton • 2 Apr 2019
Approval of Dvd for myeloma at first relapse in the UK: impacts on care 0:40
Approval of Dvd for myeloma at first relapse in the UK: impacts on care
Tanya Burton • 2 Apr 2019

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals